⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NUVB News
Nuvation Bio Inc.
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
prnewswire.com
NUVB
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
prnewswire.com
NUVB
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
prnewswire.com
NUVB
Nuvation Bio to Participate in Upcoming Investor Conferences
prnewswire.com
NUVB
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
prnewswire.com
NUVB
Form 8-K
sec.gov
NUVB
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
prnewswire.com
NUVB
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
prnewswire.com
NUVB
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
prnewswire.com
NUVB
Form 8-K
sec.gov
NUVB